Overview

Single Subject Neratinib in Bladder Cancer (NRR)

Status:
No longer available

Trial end date:
2014-06-01

Target enrollment:

Participant gender:

Summary

This study will be a single subject study to evaluate the efficacy of the HER2 kinase inhibitor, neratinib, in a patient with metastatic bladder cancer harboring a HER2-GRB7 gene fusion.

Details

Lead Sponsor:

UNC Lineberger Comprehensive Cancer Center